Loading
AB
Avidity Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Aug 2021.
Avidity Biosciences, Inc.: what insiders have been doing
Avidity Biosciences, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 39 filings were filed, from 17 insiders.
All open-market trades in the period are sales: 13 sales worth €2.5M, by 8 insiders, with no purchase on record. The largest single trade was a sale of €530k by Boyce Sarah, published on 9 January 2026.
Compared with its exchange (5,812 companies, median 19 filings), a count of 39 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 1 purchase and 49 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 18.8 m USD and net income at -684.6 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
178
Thresholds
n/a
Buy Volume
€12M
1 ops. · all time
Sell Volume
€14M
49 ops. · all time
Who traded when
BuySaleMichael F. MacLean7 sales
Sarah Boyce5 sales
Steven George Hughes5 sales
Teresa McCarthy5 sales
W. Michael Flanagan5 sales
Kathleen P. Gallagher3 sales
+5 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
Income statement
Revenue16.7M
Net income-610.6M-3650.4% margin
Last declaration on 27 February 2026
Declarations178 total
165,296 sharesCommon StockSEC:0001193125-26-082316:0
6,692 sharesCommon StockSEC:0001193125-26-082311:0
133,977 sharesCommon StockSEC:0001193125-26-082300:0
6,692 sharesCommon StockSEC:0001193125-26-082290:0
115,857 sharesCommon StockSEC:0001193125-26-082277:0
474,861 sharesCommon StockSEC:0001193125-26-082275:0
92,054 sharesCommon StockSEC:0001193125-26-082268:0
150,365 sharesCommon StockSEC:0001193125-26-082261:0
65,091 sharesCommon StockSEC:0001193125-26-082251:0
80,303 sharesCommon StockSEC:0001193125-26-082228:0
6,692 sharesCommon StockSEC:0001193125-26-082217:0
6,692 sharesCommon StockSEC:0001193125-26-082192:0
16,562 sharesCommon StockSEC:0001193125-26-082154:0
6,692 sharesCommon StockSEC:0001193125-26-082136:0
6,692 sharesCommon StockSEC:0001193125-26-082132:0
79,413 sharesCommon StockSEC:0001193125-26-082120:0
98,547 sharesCommon StockSEC:0001193125-26-082119:0
1,807 shares@ US$72.452.3% of flowCommon StockSEC:0001599901-26-000023:0
2,017 shares@ US$72.4513.8% of flowCommon StockSEC:0001599901-26-000026:0
6,394 shares@ US$72.4511.0% of flowCommon StockSEC:0001599901-26-000025:0
3,976 shares@ US$72.454.4% of flowCommon StockSEC:0001599901-26-000024:0
1,758 shares@ US$72.452.1% of flowCommon StockSEC:0001599901-26-000022:0
1,476 shares@ US$72.453.0% of flowCommon StockSEC:0001599901-26-000021:0
1,974 shares@ US$72.232.5% of flowCommon StockSEC:0001599901-26-000010:0
8,576 shares@ US$72.2314.8% of flowCommon StockSEC:0001599901-26-000014:0
25 of 178 declarations
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker RNA in the United States. Headquartered in San Diego, California, the company was founded in 2012 as Avidity NanoMedicines LLC and later converted into Avidity Biosciences, Inc. in 2019. Avidity is positioned as a next-generation RNA therapeutics company, built around its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which is designed to deliver oligonucleotides to hard-to-reach tissues, especially muscle.
The company’s business model is centered on research, clinical development, and eventual commercialization of precision medicines for rare neuromuscular diseases. Avidity’s core pipeline includes three clinical programs targeting three distinct rare disorders: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Its lead product candidate, delpacibart etedesiran (del-desiran, AOC 1001), is being developed for DM1; delpacibart braxlosiran (del-brax) targets FSHD; and delpacibart zotadirsen (del-zota) is advancing in DMD. Beyond muscle biology, the company has also stated that it is expanding the reach of AOCs into additional therapeutic areas through internal discovery and strategic partnerships.
Read moreShow less
From a competitive standpoint, Avidity operates in a highly capital-intensive specialty biotechnology segment where value creation depends on clinical validation, delivery precision, and the ability to translate late-stage data into regulatory approvals. Its differentiation lies in its delivery technology: rather than treating RNA therapeutics as a broad platform alone, Avidity is trying to solve one of the field’s key limitations by achieving more effective tissue targeting. That makes the company a potentially important player in RNA medicines, but also one with meaningful binary risk tied to clinical outcomes, regulatory decisions, and execution on commercialization.
Recent developments highlight both clinical progress and an increasingly advanced pipeline. In 2025, Avidity said it had aligned with the FDA on accelerated and full approval pathways for del-brax in FSHD, reported positive topline Phase 1/2 FORTITUDE data, and initiated a global confirmatory Phase 3 study. The company also said it remained on track to submit the BLA for del-zota in DMD at year-end 2025, with a goal of multiple regulatory submissions over a 12-month period. Combined with management’s commentary around a cash runway that supports development and launch preparation, these milestones reinforce Avidity’s profile as a high-growth health-care stock on the NASDAQ that investors will monitor for execution, clinical data, and regulatory catalysts.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
